ACCESSIBILITY

24/7

Headlines

18:20

The World Cup warning: Riots don’t start in the streets. They start online

18:07

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

14:18

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

13:32

“There is no better solution for Zim than the one we created”

Buzz

Most popular

Daily

Weekly

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat

"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"

Echo: “Employees have become very good at identifying performative culture”

“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal

More news

Pharmaceutical

12 stories about Pharmaceutical

Kibbutz-Owned Food Manufacturer Maabarot Bids for Teva’s North Israel Facility

16.10.18|Golan Hazani

Last week, Calcalist reported that Teva was nearing the sale of its Kiryat Shmona facility to German pharmaceutical device company B. Braun

Teva Nearing Sale of Israeli Manufacturing Plant

09.10.18|Golan Hazani

The pharmaceutical company is negotiating the sale of a manufacturing facility located in the town Kiryat Shmona in the north of Israel

Teva Outsources Manufacturing in Anticipation of Israeli Plant Closure

27.08.18|Golan Hazani

The debt-laden drugmaker announced an aggressive reorganization plan in December, consisting of wide-spread asset divestments and layoffs, including in its home country of Israel

Israeli Cannabis Startup InnoCan Pharma Raises $800,000 Via Crowdfunding

27.08.18|Lilach Baumer

InnoCan develops medication for psoriasis and muscle and joint pains. Its management team includes former senior executives at Teva and Pfizer

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer

The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen

Drugmaker Hikma Appoints Former Teva Executive as CEO

20.02.18|Asaf Shalev

The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit

Merck Group Inaugurates Jerusalem Innovation Lab

07.02.18|Lilach Baumer

The new lab is located at Merck subsidiary Qlight Nanotech, acquired by the pharmaceutical company in 2015

Danish Leo Pharma is Launching an Innovation Lab in Israel

04.02.18|Lilach Baumer

Established in 2015, Leo Pharma’s innovation lab currently operates in Copenhagen, London, Paris, and Toronto, developing digital health solutions

Following U.S. Bribe Settlement, Teva to Pay $22 Million Fine in Israel

15.01.18|Tomer Ganon

Yesterday, the Israeli state attorney settled a suit against the company. In 2016, Teva agreed to pay $519 million to settle anti-bribery violations in the U.S.

Moody’s Downgrades Teva Bond Rating to “Junk”

14.01.18|Lilach Baumer

The credit rating agency is following is the steps of Fitch, which did the same in November. Of the “big three,” only S&P Global still rates Teva as investment grade

Pontifax Raises a $240 Million Fifth Fund

01.01.18|Meir Orbach

Life sciences-focused venture capital firm Pontifax is expected to invest most of the new fund in the pharmaceutical industry

Teva Might Have Been Better Off as a Smaller Company, new CEO Says

17.12.17|Dror Reich

The generic drugs powerhouse is now carrying a $34.7 billion debt—a result of a $40.5 acquisition of Actavis. New CEO Kåre Schultz presented a detailed restructuring plan on Thursday